Form 4: Senti Biosciences Director Granted Stock Options Under Compensation Plan

Senti Biosciences, Inc. Director Feng Hsiung was granted 21,950 stock options with an exercise price of $2.05, vesting over one year or by the 2026 Annual Meeting, as disclosed in a recent SEC Form 4 filing.

Summary

• Director Feng Hsiung of Senti Biosciences, Inc. (SNTI) was granted 21,950 stock options on June 25, 2025.
• The stock options have an exercise price of $2.05 per share.
• The options are set to expire on June 24, 2035.
• The shares underlying these options will vest 100% upon the earlier of the first anniversary of the grant date (June 25, 2026) or the date of the 2026 Annual Meeting, contingent on the reporting person's continued service.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between management and shareholder interests, and a standard practice. It doesn't indicate any immediate negative news, but also isn't a major positive catalyst on its own.

Positives

• The grant of stock options to a director helps align their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company's strategic objectives.

Risks

• The value of the granted stock options is contingent on Senti Biosciences, Inc.'s common stock price exceeding the $2.05 exercise price in the future.
• Unvested options will be forfeited if the director's service terminates before the applicable vesting date.

Future Outlook

The grant of stock options with a defined vesting schedule signals an expectation of continued service from the director and a long-term commitment to the company's performance and growth.

Industry Context

Stock option grants are a prevalent form of executive and director compensation within the biotechnology and broader public company sectors. This practice aims to align the interests of company leadership with shareholder value creation, a standard approach for publicly traded entities like Senti Biosciences.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across the biotechnology and broader public company landscape, similar to companies like Moderna (MRNA) or BioNTech (BNTX) which also utilize equity-based incentives for their leadership.
• The vesting schedule, typically over one to four years, is also common, ensuring retention and performance alignment. A 1-year cliff or performance-based vesting is frequently observed.
• The exercise price being at or above the market price on the grant date (implied by $0 price of derivative security and $2.05 exercise price) is standard for incentive stock options.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases.
• Employees: No direct impact on general employees from this specific filing.

Next Steps

• The stock options will vest upon the earlier of June 25, 2026, or the date of the 2026 Annual Meeting, subject to continued service.
• Director Feng Hsiung may choose to exercise the options at any time after vesting and before the expiration date of June 24, 2035, assuming the stock price is above the exercise price.

Key Dates

Recommendation

Keywords

Senti Biosciences, SNTI, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Form 4, Rule 10b5-1, Biotechnology